Today, BioXcel announced that it has teamed up with Takeda’s US-based global development group to repurpose assets into new therapies for rare diseases.
BioXcel, a global leader in providing cloud-based Pharma big data solutions for discovering novel products, said that it has entered into a partnership with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases.
The companies did not disclose financial terms of the deal.
Through the partnership, Takeda will gain access to and leverage BioXcel’s Big Data Innovation Lab – an integrated product discovery engine – and PharmGPS Orphan Disease Suite for drug discovery and repurposing.
The PharmGPS Orphan Disease Suite is BioXcel’s live and multi-dimensional platform. The proprietary suite encompasses more than 9,000 rare and ultra-rare diseases, 4,000-5,000 associated genes, 1,500 disease pathways, and distinct target-indication tiles for antibody, protein, RNA, small molecule and gene therapy modalities. BioXcel says that PharmaGPS enables commercialization of orphan drugs either through de novo drug discovery, or repurposing and reformulation of older compounds based on disease severity, gene ontology, disease pathways, proteinopathy, standard of care, emerging innovation, enabling technologies and current drug pipeline – all of which are considered crucial when addressing the high unmet need of patients with rare and ultra-rare diseases.
“We are pleased that Takeda will leverage our expertise in rare and ultra rare diseases to support their innovation and portfolio expansion initiatives. Discovering novel applications for existing molecules in an increasingly attractive strategy to address patient needs, while capitalizing on previous investments and de-risking clinical development. Our Big Data Innovation Lab facilitates the repurposing of the most attractive candidates applicable to a given disease,” said Vinal Mehta, PhD, CEO and Chairman of BioXcel.
Earlier this year, BioXcel initiated a big data project with Alexion to prioritize pertinent sets of rare diseases for relevant therapeutic modalities.
Source: BioXcel Corporation
Last updated: 4/9/15; 1:50pm EST